…TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system.
The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or more importantly, ANY cancer, infectious disease or bio-threat.
…It is my pleasure to provide an update to existing and potentially new shareholders on the progress we have made over the past few months.
Highlights from the below detailed update include:
Positive progress at the MAYO clinic on the phase 1 HER2/neu clinical trial with interim results expected in the near term.
…ANCOUVER, Canada, 31 July, 2007 – TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, opens new laboratory facilities and provides this update to shareholders.
The opening of the new laboratory facility in Vancouver facilitates the transfer of its technology from The University of British Columbia and signifies the start of the Pre-Clinical process to commercialize its core TAP technologies.
…VANCOUVER, British Columbia, July 17, 2007 (PRIME NEWSWIRE) — TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has launched a new corporate website with links to media features on its technologies.
“I am pleased to have this resource available to our shareholders and other interested parties as it provides a comprehensive look at the company and our technology,” said TapImmune Inc.
…New Name to Reflect a New Direction and Independent Operation
VANCOUVER, BC – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced today that it has fulfilled its financial obligation to The University of British Columbia for the proposed acquisition of its key Transporter Associated with Antigen Processing (TAP) technology platform and patents.